Artemisinin Action and Resistance in Plasmodium falciparum

Trends in Parasitology

Volumn 32, Issue 9, 2016, Pages 682-696

  Tilley, Leann ^a   Straimer, Judith ^b   Gnädig, Nina F ^b   Ralph, Stuart A ^a   Fidock, David A ^b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

artemisinin resistance; Kelch13; malaria.; proteasome; ubiquitination; unfolded protein response

Indexed keywords

ARTEFENOMEL; ARTEMISININ; ARTEROLANE; ARTESUNATE PLUS MEFLOQUINE; K 13; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; PROTOZOAL PROTEIN;

ANTIBIOTIC RESISTANCE; CELL DEATH; CELL SURVIVAL; CELLULAR STRESS RESPONSE; CHEMICAL STRUCTURE; DRUG ACTIVATION; DRUG POTENCY; DRUG TARGETING; GENE MUTATION; HUMAN; MALARIA; NONHUMAN; PARASITE CLEARANCE; PHASE 2 CLINICAL TRIAL (TOPIC); PLASMODIUM FALCIPARUM; POLYPHARMACY; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SURVIVAL RATE; TREATMENT FAILURE; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; MALARIA, FALCIPARUM; MUTATION; PARASITOLOGY;

ANTIMALARIALS; ARTEMISININS; DRUG RESISTANCE; MALARIA, FALCIPARUM; MUTATION; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS;

EID: 84991594101     PISSN: 14714922     EISSN: 14715007     Source Type: Journal    
DOI: 10.1016/j.pt.2016.05.010     Document Type: Review

References (127)

1. 1 World Health Organization, World Malaria Report 2015., 2015, World Health Organization (http://www.who.int/malaria/publications/world-malaria-report-2015/report/en).
2. 2 Meunier, B., Robert, A., Heme as trigger and target for trioxane-containing antimalarial drugs. Acc. Chem. Res. 43 (2010), 1444–1451.
3. 3 O'Neill, P.M., Posner, G.H., A medicinal chemistry perspective on artemisinin and related endoperoxides. J. Med. Chem. 47 (2004), 2945–2964.
4. 4 Eastman, R.T., Fidock, D.A., Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria. Nat. Rev. Microbiol. 7 (2009), 864–874.
5. 5 White, N.J., Qinghaosu (artemisinin): the price of success. Science 320 (2008), 330–334.
6. 6 White, N.J., et al. Malaria. Lancet 383 (2014), 723–735.
7. 7 Dondorp, A.M., et al. Artemisinin resistance in Plasmodium falciparum malaria. N. Engl. J. Med. 361 (2009), 455–467.
8. 8 Enserink, M., Malaria's drug miracle in danger. Science 328 (2010), 844–846.
9. 9 White, N.J., Pharmacokinetic and pharmacodynamic considerations in antimalarial dose optimization. Antimicrob. Agents Chemother. 57 (2013), 5792–5807.
10. 10 Vennerstrom, J.L., et al. Identification of an antimalarial synthetic trioxolane drug development candidate. Nature 430 (2004), 900–904.
11. 11 Kaiser, M., et al. Peroxide bond-dependent antiplasmodial specificity of artemisinin and OZ277 (RBx11160). Antimicrob. Agents Chemother. 51 (2007), 2991–2993.
12. 12 Wells, T.N., et al. Malaria medicines: a glass half full?. Nat. Rev. Drug Discov. 14 (2015), 424–442.
13. 13 Valecha, N., et al. Arterolane maleate plus piperaquine phosphate for treatment of uncomplicated Plasmodium falciparum malaria: a comparative, multicenter, randomized clinical trial. Clin. Infect. Dis. 55 (2012), 663–671.
14. 14 Charman, S.A., et al. Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria. Proc. Natl. Acad. Sci. U.S.A. 108 (2011), 4400–4405.
15. 15 Gautam, A., et al. Pharmacokinetics and pharmacodynamics of arterolane maleate following multiple oral doses in adult patients with P. falciparum malaria. J. Clin. Pharmacol. 51 (2011), 1519–1528.
16. 16 Saha, N., et al. Safety, tolerability and pharmacokinetic profile of single and multiple oral doses of arterolane (RBx11160) maleate in healthy subjects. J. Clin. Pharmacol. 54 (2014), 386–393.
17. 17 Phyo, A.P., et al. Antimalarial activity of artefenomel (OZ439), a novel synthetic antimalarial endoperoxide, in patients with Plasmodium falciparum and Plasmodium vivax malaria: an open-label phase 2 trial. Lancet Infect. Dis. 16 (2016), 61–69.
18. 18 Rosenthal, P.J., Artefenomel: a promising new antimalarial drug. Lancet Infect. Dis. 16 (2016), 6–8.
19. 19 Moehrle, J.J., et al. First-in-man safety and pharmacokinetics of synthetic ozonide OZ439 demonstrates an improved exposure profile relative to other peroxide antimalarials. Br. J. Clin. Pharmacol. 75 (2013), 524–537.
20. 20 Meshnick, S.R., et al. Artemisinin (Qinghaosu): the role of intracellular hemin in its mechanism of antimalarial action. Mol. Biochem. Parasitol. 49 (1991), 181–189.
21. 21 Klonis, N., et al. Iron and heme metabolism in Plasmodium falciparum and the mechanism of action of artemisinins. Curr. Opin. Microbiol. 16 (2013), 722–727.
22. 22 Abu Bakar, N.A., et al. Digestive-vacuole genesis and endocytic processes in the early intraerythrocytic stages of Plasmodium falciparum. J. Cell Sci. 123 (2010), 441–450.
23. 23 Meyers, M.J., Goldberg, D.E., Recent advances in plasmepsin medicinal chemistry and implications for future antimalarial drug discovery efforts. Curr. Top. Med. Chem. 12 (2012), 445–455.
24. 24 Rosenthal, P.J., Falcipains and other cysteine proteases of malaria parasites. Adv. Exp. Med. Biol. 712 (2011), 30–48.
25. 25 Egan, T.J., Haemozoin formation. Mol. Biochem. Parasitol. 157 (2008), 127–136.
26. 26 Combrinck, J.M., et al. Insights into the role of heme in the mechanism of action of antimalarials. ACS Chem. Biol. 8 (2013), 133–137.
27. 27 Klonis, N., et al. Altered temporal response of malaria parasites determines differential sensitivity to artemisinin. Proc. Natl. Acad. Sci. U.S.A. 110 (2013), 5157–5162.
28. 28 Adjalley, S.H., et al. Quantitative assessment of Plasmodium falciparum sexual development reveals potent transmission-blocking activity by methylene blue. Proc. Natl. Acad. Sci. U.S.A. 108 (2011), E1214–E1223.
29. 29 Meister, S., et al. Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery. Science 334 (2011), 1372–1377.
30. 30 Xie, S.C., et al. Haemoglobin degradation underpins the sensitivity of early ring stage Plasmodium falciparum to artemisinins. J. Cell Sci. 129 (2016), 406–416.
31. 31 Surolia, N., Padmanaban, G., De novo biosynthesis of heme offers a new chemotherapeutic target in the human malarial parasite. Biochem. Biophys. Res. Commun. 187 (1992), 744–750.
32. 32 Wang, J., et al. Haem-activated promiscuous targeting of artemisinin in Plasmodium falciparum. Nat. Commun., 6, 2015, 10111.
33. 33 Ke, H., et al. The heme biosynthesis pathway is essential for Plasmodium falciparum development in mosquito stage but not in blood stages. J. Biol. Chem. 289 (2014), 34827–34837.
34. 34 Clark, M., et al. Parasite maturation and host serum iron influence the labile iron pool of erythrocyte stage Plasmodium falciparum. Br. J. Haematol. 161 (2013), 262–269.
35. 35 Loria, P., et al. Inhibition of the peroxidative degradation of haem as the basis of action of chloroquine and other quinoline antimalarials. Biochem. J. 339 (1999), 363–370.
36. 36 Ginsburg, H., et al. Inhibition of glutathione-dependent degradation of heme by chloroquine and amodiaquine as a possible basis for their antimalarial mode of action. Biochem. Pharmacol. 56 (1998), 1305–1313.
37. 37 Eckstein-Ludwig, U., et al. Artemisinins target the SERCA of Plasmodium falciparum. Nature 424 (2003), 957–961.
38. 38 Stocks, P.A., et al. Evidence for a common non-heme chelatable-iron-dependent activation mechanism for semisynthetic and synthetic endoperoxide antimalarial drugs. Angew. Chem. Int. Ed. Engl. 46 (2007), 6278–6283.
39. 39 Haynes, R.K., et al. Interactions between artemisinins and other antimalarial drugs in relation to the cofactor model–a unifying proposal for drug action. ChemMedChem 7 (2012), 2204–2226.
40. 40 Wang, J., et al. Artemisinin directly targets malarial mitochondria through its specific mitochondrial activation. PLoS ONE, 5, 2010, e9582.
41. 41 Dogovski, C., et al. Targeting the cell stress response of Plasmodium falciparum to overcome artemisinin resistance. PLoS Biol., 13, 2015, e1002132.
42. 42 O'Neill, P.M., et al. The molecular mechanism of action of artemisinin – the debate continues. Molecules 15 (2010), 1705–1721.
43. 43 Li, J., Zhou, B., Biological actions of artemisinin: insights from medicinal chemistry studies. Molecules 15 (2010), 1378–1397.
44. 44 Meshnick, S.R., Artemisinin: mechanisms of action, resistance and toxicity. Int. J. Parasitol. 32 (2002), 1655–1660.
45. 45 Krishna, S., et al. Artemisinins: mechanisms of action and potential for resistance. Drug Resist. Updat. 7 (2004), 233–244.
46. 46 Maeno, Y., et al. Morphologic effects of artemisinin in Plasmodium falciparum. Am. J. Trop. Med. Hyg. 49 (1993), 485–491.
47. 47 Pandey, A.V., et al. Artemisinin, an endoperoxide antimalarial, disrupts the hemoglobin catabolism and heme detoxification systems in malarial parasite. J. Biol. Chem. 274 (1999), 19383–19388.
48. 48 Crespo, M.D.P., et al. Artemisinin and a series of novel endoperoxide antimalarials exert early effects on digestive vacuole morphology. Antimicrob. Agents Chemother. 52 (2008), 98–109.
49. 49 Hartwig, C.L., et al. Accumulation of artemisinin trioxane derivatives within neutral lipids of Plasmodium falciparum malaria parasites is endoperoxide-dependent. Biochem. Pharmacol. 77 (2009), 322–336.
50. 50 Ismail, H.M., et al. Artemisinin activity-based probes identify multiple molecular targets within the asexual stage of the malaria parasites Plasmodium falciparum 3D7. Proc. Natl. Acad. Sci. U.S.A. 113 (2016), 2080–2085.
51. 51 Florens, L., et al. A proteomic view of the Plasmodium falciparum life cycle. Nature 419 (2002), 520–526.
52. 52 Silvestrini, F., et al. Protein export marks the early phase of gametocytogenesis of the human malaria parasite Plasmodium falciparum. Mol. Cell. Proteomics 9 (2010), 1437–1448.
53. 53 Treeck, M., et al. The phosphoproteomes of Plasmodium falciparum and Toxoplasma gondii reveal unusual adaptations within and beyond the parasites’ boundaries. Cell Host Microbe 10 (2011), 410–419.
54. 54 Lisewski, A.M., et al. Supergenomic network compression and the discovery of EXP1 as a glutathione transferase inhibited by artesunate. Cell 158 (2014), 916–928.
55. 55 Akompong, T., et al. Artemisinin and its derivatives are transported by a vacuolar-network of Plasmodium falciparum and their antimalarial activities are additive with toxic sphingolipid analogues that block the network. Mol. Biochem. Parasitol. 101 (1999), 71–79.
56. 56 Klonis, N., et al. Artemisinin activity against Plasmodium falciparum requires hemoglobin uptake and digestion. Proc. Natl. Acad. Sci. U.S.A. 108 (2011), 11405–11410.
57. 57 Mbengue, A., et al. A molecular mechanism of artemisinin resistance in Plasmodium falciparum malaria. Nature 520 (2015), 683–687.
58. 58 Vaid, A., et al. PfPI3K, a phosphatidylinositol-3 kinase from Plasmodium falciparum, is exported to the host erythrocyte and is involved in hemoglobin trafficking. Blood 115 (2010), 2500–2507.
59. 59 Hoppe, H.C., et al. Antimalarial quinolines and artemisinin inhibit endocytosis in Plasmodium falciparum. Antimicrob. Agents Chemother. 48 (2004), 2370–2378.
60. 60 Paloque, L., et al. Plasmodium falciparum: multifaceted resistance to artemisinins. Malar. J., 15, 2016, 149.
61. 61 Henriques, G., et al. Artemisinin resistance in rodent malaria–mutation in the AP2 adaptor mu-chain suggests involvement of endocytosis and membrane protein trafficking. Malar. J., 12, 2013, 118.
62. 62 Robert, A., et al. Correlation between Plasmodium yoelii nigeriensis susceptibility to artemisinin and alkylation of heme by the drug. Antimicrob. Agents Chemother. 57 (2013), 3998–4000.
63. 63 Ashley, E.A., et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. N. Engl. J. Med. 371 (2014), 411–423.
64. 64 WHO Malaria Policy Advisory Committee and Secretariat, Malaria Policy Advisory Committee to the WHO: conclusions and recommendations of eighth biannual meeting (September 2015). Malar. J., 15, 2016, 117.
65. 65 Phyo, A.P., et al. Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study. Lancet 379 (2012), 1960–1966.
66. 66 Amaratunga, C., et al. Artemisinin-resistant Plasmodium falciparum in Pursat province, western Cambodia: a parasite clearance rate study. Lancet Infect. Dis. 12 (2012), 851–858.
67. 67 Witkowski, B., et al. Novel phenotypic assays for the detection of artemisinin-resistant Plasmodium falciparum malaria in Cambodia: in-vitro and ex-vivo drug-response studies. Lancet Infect. Dis. 13 (2013), 1043–1049.
68. 68 Amaratunga, C., et al. Artemisinin resistance in Plasmodium falciparum. Lancet Infect. Dis. 14 (2014), 449–450.
69. 69 Cheeseman, I.H., et al. A major genome region underlying artemisinin resistance in malaria. Science 336 (2012), 79–82.
70. 70 Takala-Harrison, S., et al. Genetic loci associated with delayed clearance of Plasmodium falciparum following artemisinin treatment in Southeast Asia. Proc. Natl. Acad. Sci. U.S.A. 110 (2013), 240–245.
71. 71 Miotto, O., et al. Multiple populations of artemisinin-resistant Plasmodium falciparum in Cambodia. Nat. Genet. 45 (2013), 648–655.
72. 72 Witkowski, B., et al. Increased tolerance to artemisinin in Plasmodium falciparum is mediated by a quiescence mechanism. Antimicrob. Agents Chemother. 54 (2010), 1872–1877.
73. 73 Ariey, F., et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature 505 (2014), 50–55.
74. 74 Ghorbal, M., et al. Genome editing in the human malaria parasite Plasmodium falciparum using the CRISPR-Cas9 system. Nat. Biotechnol. 32 (2014), 819–821.
75. 75 Straimer, J., et al. K13-propeller mutations confer artemisinin resistance in Plasmodium falciparum clinical isolates. Science 347 (2015), 428–431.
76. 76 Talundzic, E., et al. Selection and spread of artemisinin-resistant alleles in Thailand prior to the global artemisinin resistance containment campaign. PLoS Pathog., 11, 2015, e1004789.
77. 77 Wang, Z., et al. Prevalence of K13-propeller polymorphisms in Plasmodium falciparum from China–Myanmar border in 2007-2012. Malar. J., 14, 2015, 168.
78. 78 Huang, F., et al. A single mutation in K13 predominates in southern China and is associated with delayed clearance of Plasmodium falciparum following artemisinin treatment. J. Infect. Dis. 212 (2015), 1629–1635.
79. 79 MalariaGEN Plasmodium falciparum Community Project, Genomic epidemiology of artemisinin resistant malaria. eLife, 5, 2016, e08714.
80. 80 Ouattara, A., et al. Polymorphisms in the K13-propeller gene in artemisinin-susceptible Plasmodium falciparum parasites from Bougoula-Hameau and Bandiagara. Mali. A. J. Trop. Med. Hyg. 92 (2015), 1202–1206.
81. 81 Cooper, R.A., et al. Lack of artemisinin resistance in Plasmodium falciparum in Uganda based on parasitological and molecular assays. Antimicrob. Agents Chemother. 59 (2015), 5061–5064.
82. 82 Muwanguzi, J., et al. Lack of K13 mutations in Plasmodium falciparum persisting after artemisinin combination therapy treatment of Kenyan children. Malar. J., 15, 2016, 36.
83. 83 Taylor, S.M., et al. Absence of putative artemisinin resistance mutations among Plasmodium falciparum in Sub-Saharan Africa: a molecular epidemiologic study. J. Infect. Dis. 211 (2015), 680–688.
84. 84 Fairhurst, R.M., Understanding artemisinin-resistant malaria: what a difference a year makes. Curr. Opin. Infect. Dis. 28 (2015), 417–425.
85. 85 Ron, D., Walter, P., Signal integration in the endoplasmic reticulum unfolded protein response. Nat. Rev. Mol. Cell. Biol. 8 (2007), 519–529.
86. 86 Amm, I., et al. Protein quality control and elimination of protein waste: the role of the ubiquitin-proteasome system. Biochim. Biophys. Acta 1843 (2014), 182–196.
87. 87 Zhang, M., et al. PK4, a eukaryotic initiation factor 2α (eIF2α) kinase, is essential for the development of the erythrocytic cycle of Plasmodium. Proc. Natl. Acad. Sci. U.S.A. 109 (2012), 3956–3961.
88. 88 Tucker, M.S., et al. Phenotypic and genotypic analysis of in vitro-selected artemisinin-resistant progeny of Plasmodium falciparum. Antimicrob. Agents Chemother. 56 (2012), 302–314.
89. 89 Hott, A., et al. Artemisinin-resistant Plasmodium falciparum parasites exhibit altered patterns of development in infected erythrocytes. Antimicrob. Agents Chemother. 59 (2015), 3156–3167.
90. 90 Mok, S., et al. Population transcriptomics of human malaria parasites reveals the mechanism of artemisinin resistance. Science 347 (2014), 431–435.
91. 91 Li, H., et al. Structure- and function-based design of Plasmodium-selective proteasome inhibitors. Nature 530 (2016), 233–236.
92. 92 Hunt, P., et al. Gene encoding a deubiquitinating enzyme is mutated in artesunate- and chloroquine-resistant rodent malaria parasites. Mol. Microbiol. 65 (2007), 27–40.
93. 93 Adams, J., et al. The kelch repeat superfamily of proteins: propellers of cell function. Trends Cell. Biol. 10 (2000), 17–24.
94. 94 Dhanoa, B.S., et al. Update on the Kelch-like (KLHL) gene family. Hum. Genomics, 7, 2013, 13.
95. 95 Bardwell, V.J., Treisman, R., The POZ domain: a conserved protein–protein interaction motif. Genes Dev. 8 (1994), 1664–1677.
96. 96 Perez-Torrado, R., et al. Born to bind: the BTB protein–protein interaction domain. Bioessays 28 (2006), 1194–1202.
97. 97 Ding, X.F., et al. Characterization and expression of a human KCTD1 gene containing the BTB domain, which mediates transcriptional repression and homomeric interactions. DNA Cell Biol. 27 (2008), 257–265.
98. 98 Furukawa, M., et al. Targeting of protein ubiquitination by BTB–Cullin 3–Roc1 ubiquitin ligases. Nat. Cell Biol. 5 (2003), 1001–1007.
99. 99 Stogios, P.J., et al. Sequence and structural analysis of BTB domain proteins. Genome Biol., 6, 2005, R82.
100. 100 Digaleh, H., et al. Nrf2 and Nrf1 signaling and ER stress crosstalk: implication for proteasomal degradation and autophagy. Cell. Mol. Life Sci. 70 (2013), 4681–4694.
101. 101 Cullinan, S.B., et al. Nrf2 is a direct PERK substrate and effector of PERK-dependent cell survival. Mol. Cell. Biol. 23 (2003), 7198–7209.
102. 102 Lacher, S.E., et al. Beyond antioxidant genes in the ancient Nrf2 regulatory network. Free Radic. Biol. Med. 88 (2015), 452–465.
103. 103 Gacesa, R., et al. Bioinformatics analyses provide insight into distant homology of the Keap1–Nrf2 pathway. Free Radic. Biol. Med. 88 (2015), 373–380.
104. 104 Bischoff, E., Vaquero, C., In silico and biological survey of transcription-associated proteins implicated in the transcriptional machinery during the erythrocytic development of Plasmodium falciparum. BMC Genomics, 11, 2010, 34.
105. 105 Miotto, O., et al. Genetic architecture of artemisinin resistant Plasmodium falciparum. Nat. Genet. 47 (2015), 226–234.
106. 106 Sidhu, A.B., et al. Chloroquine resistance in Plasmodium falciparum malaria parasites conferred by pfcrt mutations. Science 298 (2002), 210–213.
107. 107 Price, R.N., et al. Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. Lancet 364 (2004), 438–447.
108. 108 Sidhu, A.B., et al. Decreasing pfmdr1 copy number in Plasmodium falciparum malaria heightens susceptibility to mefloquine, lumefantrine, halofantrine, quinine, and artemisinin. J. Infect. Dis. 194 (2006), 528–535.
109. 109 Petersen, I., et al. Drug-resistant malaria: molecular mechanisms and implications for public health. FEBS Lett. 585 (2011), 1551–1562.
110. 110 Veiga, M.I., et al. Globally prevalent PfMDR1 mutations modulate Plasmodium falciparum susceptibility to artemisinin-based combination therapies. Nat. Commun., 7, 2016, 11553.
111. 111 Venkatesan, M., et al. Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether–lumefantrine and artesunate–amodiaquine. Am. J. Trop. Med. Hyg. 91 (2014), 833–843.
112. 112 Petersen, I., et al. Balancing drug resistance and growth rates via compensatory mutations in the Plasmodium falciparum chloroquine resistance transporter. Mol. Microbiol. 97 (2015), 381–395.
113. 113 Yang, T., et al. A comparison of the exposure time-dependence of the activities of synthetic ozonide antimalarials and dihydroartemisinin against K13 wildtype and mutant Plasmodium falciparum. Antimicrob. Agents Chemother., 2016, 10.1128/AAC.00574-16.
114. 114 Li, H., et al. Validation of the proteasome as a therapeutic target in Plasmodium using an epoxyketone inhibitor with parasite-specific toxicity. Chem. Biol. 19 (2012), 1535–1545.
115. 115 Tschan, S., et al. Broad-spectrum antimalarial activity of peptido sulfonyl fluorides, a new class of proteasome inhibitors. Antimicrob. Agents Chemother. 57 (2013), 3576–3584.
116. 116 Li, H., et al. Identification of potent and selective non-covalent inhibitors of the Plasmodium falciparum proteasome. J. Am. Chem. Soc. 136 (2014), 13562–13565.
117. 117 Copple, I.M., The Keap1–Nrf2 cell defense pathway–a promising therapeutic target?. Adv. Pharmacol. 63 (2012), 43–79.
118. 118 Amaratunga, C., et al. Dihydroartemisinin–piperaquine resistance in Plasmodium falciparum malaria in Cambodia: a multisite prospective cohort study. Lancet Infect. Dis. 16 (2016), 357–365.
119. 119 Spring, M.D., et al. Dihydroartemisinin–piperaquine failure associated with a triple mutant including kelch13 C580Y in Cambodia: an observational cohort study. Lancet Infect. Dis. 15 (2015), 683–691.
120. 120 Saunders, D.L., et al. Dihydroartemisinin–piperaquine failure in Cambodia. N. Eng. J. Med. 371 (2014), 484–485.
121. 121 Leang, R., et al. Efficacy of dihydroartemisinin–piperaquine for treatment of uncomplicated Plasmodium falciparum and Plasmodium vivax in Cambodia, 2008 to 2010. Antimicrob. Agents Chemother. 57 (2013), 818–826.
122. 122 Leang, R., et al. Evidence of Plasmodium falciparum malaria multidrug resistance to artemisinin and piperaquine in Western Cambodia: dihydroartemisinin–piperaquine open-label multicenter clinical assessment. Antimicrob. Agents Chemother. 59 (2015), 4719–4726.
123. 123 Na-Bangchang, K., et al. Declining in efficacy of a three-day combination regimen of mefloquine–artesunate in a multi-drug resistance area along the Thai–Myanmar border. Malar. J., 9, 2010, 273.
124. 124 Carrara, V.I., et al. Malaria burden and artemisinin resistance in the mobile and migrant population on the Thai–Myanmar border, 1999-2011: an observational study. PLoS Med., 10, 2013, e1001398.
125. 125 Witkowski, B., et al. Reduced artemisinin susceptibility of Plasmodium falciparum ring stages in western Cambodia. Antimicrob. Agents Chemother. 57 (2013), 914–923.
126. 126 Ndour, P.A., et al. Plasmodium falciparum clearance is rapid and pitting independent in immune Malian children treated with artesunate for malaria. J. Infect. Dis. 15 (2014), 290–297.
127. 127 Chotivanich, K., et al. The mechanisms of parasite clearance after antimalarial treatment of Plasmodium falciparum malaria. J. Infect. Dis. 182 (2000), 629–633.